Unsure if you have an STD?
Get started with testing options here
Search the Community
Showing results for tags 'live attenuated'.
Found 1 result
ManagingIllness posted a topic in Herpes Cure ResearchFull paper here: https://www.sciencedirect.com/science/article/pii/S0264410X18315652 Note sure if anyone wrote about this. I couldn't find any results for VC2 in the site's search. This is a live attenuated vaccine from Louisiana State University. The results do not seem super promising, as reducing shedding/recurrance by < 70% pre-clinical is common in many discontinued vaccines. Still, research is being done, which is always great! Prophylactic conclusions: "Our studies also showed that VC2 vaccine decreases the clinical severity of acute and recurrent HSV-2 disease in guinea pigs when provided by intramuscular vaccination. During the primary infection, animals vaccinated with VC2 had a significant decrease in clinical severity and replicating virus in the vaginal vault. Prophylactic vaccination also decreased the quantity of virus in the DRGs when compared to the No Treatment group. The ability to protect neural tissue from latent infection probably contributed to the decrease in the number of animals with recurrent lesions by 67% and the number of days with recurrent vaginal shedding by 46%. This reduction in shedding is particularly important because transmission of HSV-2 to uninfected persons is largely due to asymptomatic shedding , ." Theraputic conclusions: "When tested as a therapeutic vaccine, i.e., one designed to decrease recurrent disease and recurrent virus shedding in those already infected with HSV, the VC2 vaccine was not effective although it did reduce recurrent shedding, at least when compared to the gD2 vaccine. This may be because live attenuated vaccines have only limited replication in hosts that are already infected and thus do not have much of an impact in improving the immune response. Because infected hosts have frequent reactivations of virus that would be similar to a live vaccine inoculation it may be difficult for the vaccine to improve the immune response unless it is able to induce responses not activated by the host’s recurrent virus replication."